Brandon D. Lowe

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN–GIL hybrid single-molecule inhibitors”.

The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN–GIL hybrid single-molecule inhibitors

European Journal of Medicinal Chemistry(2024)10.1016/j.ejmech.2024.117190

N/A

0DataRank · unranked

7 citations

Christian Eberly, Alexandria M. Chan, Minjung Kim, Brandon D. Lowe, Curt I. Civin +2 more

First-in-Class Potent, Dual HDAC6/Proteasome Inhibitors Lacking a Hydroxamic Acid Motif: Discovery of Novel Anti-Multiple Myeloma Agents

ACS Medicinal Chemistry Letters(2025)10.1021/acsmedchemlett.5c00500

N/A

0DataRank · unranked

3 citations

Brandon D. Lowe, Andrea L. Cottingham, Daniel Van Eker, Asaminew H. Aytenfisu, Jace W. Jones +4 more